Assessing the Necessity of Prescribing Antibiotics (Clavulin or Clindamycin Versus Placebo) Post-peritonsillar Abscess Drainage (PTA)
Recruitment status was: Recruiting
|Peritonsillar Abscess||Drug: Clavulin Drug: Randomization to Placebo Drug: Clindamycin|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider)
Primary Purpose: Treatment
|Official Title:||Comparing Post-drainage Treatment of Peritonsillar Abscesses With Antibiotics (Clavulin or Clindamycin) to Treating With Placebo - a Double-blinded Randomized Control Trial|
- Re-accumulation of the patient's peri-tonsillar abscess [ Time Frame: 30 days ]Patients will be followed up at 2 time points - 7 days and 30 days. At 7 days, the patient will be called and asked to see if they have had resolution of their symptoms. We will again call within 30 days to see if symptoms have returned within that time frame.
|Study Start Date:||June 2012|
|Estimated Study Completion Date:||June 2014|
|Estimated Primary Completion Date:||June 2014 (Final data collection date for primary outcome measure)|
Active Comparator: Antibiotic Clavulin or Clindamycin
Patient's in this arm are randomized by random-number generator to receive antibiotics. This is for a 7 day course of antibiotics. Those that are allergic to penicillin will receive clindamycin. Randomization occurs after knowledge of the patient's allergy status.
Patients will be randomized to the antibiotic or placebo arm via a random number generator.Drug: Clindamycin
Patients will be randomized to the antibiotic or placebo arm via a random number generator
Placebo Comparator: Placebo
Patient's randomized to this arm post-drainage will receive placebo and not receive antibiotics
Drug: Randomization to Placebo
Patient's post-drainage of antibiotics will receive placebo and not receive antibiotics
This will be a single-blinded randomized-control trial enrolling all patients presenting to otolaryngology in London, ON with a PTA. Patients will be managed in a consistent protocol amongst team members. Diagnosis of a PTA will be made by the attending physician and/or ENT team. Patients presenting symptomatology will be recorded (e.g. trismus, dysarthria, dysphagia, documented fever, etc). Previous use of antibiotics prior to presentation will also be documented, as well as use of IV antibiotics at the time of initial assessment by the ER team. After the patient has been diagnosed, the patient will be given the option to enrol in the study. If the patient agrees to enrol in the study, the following will occur. Each patient will be randomized into one of two arms - those that will receive post-drainage antibiotics versus those that will receive placebo. If randomized to the antibiotic treatment arm, then each patient will be given Amoxicillin-clavulanic acid as the antibiotic treatment of choice for 7 days unless the patient has a pencillin-allergy. If so, they will be given clindamycin. All patients will be counselled to return to hospital if their symptoms persist. In addition, each patient will be contacted after 7 days to assess if their symptoms have resolved.
The patient's abscess aspirate will be sent for culture and sensitivity. The patient's identification number will be emailed to the study administrator via confidential hospital email and the patient will be given a unique study identification code. Pertinent epidemiological data will be collected from the emergency room consultation note dictated by the treating physician and stored in a separate database.
In the microbiology laboratory, the fluid aspirate will undergo aerobic culture. Anaerobic culture will be completed on each patient's sample that arrives, providing funding for each test has been obtained. The aerobic culture of the fluid aspirate will undergo gram stain with reporting of the specific types of bacteria seen and the bacteria will then be plated, cultured and tested for sensitivities. All patients will be contacted one week after treatment to ensure clinical resolution of disease. This will be defined as resolution of symptoms, specifically trismus, odynophagia, referred otalgia, absence of dysarthria, and overall physical improvement. If persistent symptoms of recurrent abscesses are noted, appropriate follow-up will be arranged for the patient with an otolaryngologist. No confidential identifying information will be recorded in the study database. Any complications suffered by the patient will be recorded in the database.
The study will be carried out for a total of two years. Once the study is complete, all identifying data on the SIN sheet will be confidentially destroyed. No access to the study database will be available once the study is complete.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01715610
|Contact: Murad Husein, MD,MSc,FRCS(C)||5196858184||Murad.Husein@lhsc.on.ca|
|Contact: Sammy Khalili, MDfirstname.lastname@example.org|
|London Health Sciences Center, St. Joseph's Hospital||Recruiting|
|London, Ontario, Canada, n5x4s1|
|Contact: Murad Husein, MD,MSc, FRCS(C) 5196858184 Murad.Husein@lhsc.on.ca|
|Contact: Sammy Khalili, MD 5196858184 email@example.com|
|Principal Investigator: Murad Husein, MD,MSc,FRCSC|
|Sub-Investigator: Sammy Khalili, MD|
|Sub-Investigator: Michael John, MD,FRCPC|
|Principal Investigator:||Murad Husein, MD. FRCSC||Lawson Health Research Institute|